Cargando…
EZH2: novel therapeutic target for human cancer
Enhancer of Zeste homlog 2 (EZH2) is a catalytic subunit of epigenetic regulator Polycomb repressive complex 2 (PRC2), which trimethylates Lys 27 of histone H3, leading to silencing of the target genes that are involved in a variety of biological processes including tumor progression and stem cell m...
Autor principal: | Li, Long-Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
China Medical University
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264983/ https://www.ncbi.nlm.nih.gov/pubmed/25520914 http://dx.doi.org/10.7603/s40681-014-0001-6 |
Ejemplares similares
-
EZH2 in Bladder Cancer, a Promising Therapeutic Target
por: Martínez-Fernández, Mónica, et al.
Publicado: (2015) -
EZH2: a novel target for cancer treatment
por: Duan, Ran, et al.
Publicado: (2020) -
The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer
por: Li, Zhongwu, et al.
Publicado: (2013) -
Functional and therapeutic significance of EZH2 in urological cancers
por: Liu, Xiaobing, et al.
Publicado: (2017) -
Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target
por: Wen, Yiping, et al.
Publicado: (2017)